Dossier assessment
Brolucizumab (neovascular age-related macular degeneration) – Benefit assessment according to §35a Social Code Book V (expiry of the decision)
Report documents
-
Extract of dossier assessment
Brolucizumab (neovascular age-related macular degeneration) – Benefit assessment according to §35a Social Code Book V (expiry of the decision)
-
Dossierbewertung
Brolucizumab (neovascular age-related macular degeneration) – Benefit assessment according to §35a Social Code Book V (expiry of the decision)
Dossier assessment
Adults with neovascular (wet) age-related macular degeneration
Added benefit not proven
Additional information
Federal Joint Committee (G-BA)
2024-05-02 A G-BA decision was published.
Project details
- Project no.
- A23-101
- Commission
- Commission awarded on 20.10.2023 by the Federal Joint Committee (GBA).
- Report type
- Dossier assessment
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Head and nerves
- Note
-
After completion of the assessment by IQWiG the Federal Joint Committee (GBA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the GBA website.
- DOI
https://dx.doi.org/10.60584/A23-101
Connected Projects
-
Dossier assessment
Brolucizumab (visual impairment due to diabetic macular oedema) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Brolucizumab (neovascular age-related macular degeneration) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Addendum
Brolucizumab (neovascular age-related macular degeneration) – Addendum to Project A23-101
Status: Commission completed